CDK4 and breast cancer: More recently, the targeting of cell cycle progression with cyclin-dependant kinase 4/6 (CDK4/6) inhibitors in combination with anti-oestrogen therapy has become the standard first-line therapy in de novo or recurrent breast cancer [24,25].